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Abstract
EGFR tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments 
for non-small cell lung cancers harboring activating mutations in the EGFR kinase1,2, but 
resistance arises rapidly, most frequently due to the secondary T790M mutation within the ATP-
site of the receptor.3,4 Recently developed mutant-selective irreversible inhibitors are highly active 
against the T790M mutant5,6, but their efficacy can be compromised by acquired mutation of 
C797, the cysteine residue with which they form a key covalent bond7. All current EGFR TKIs 
target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternate 
mechanisms of action. Here we describe rational discovery of EAI045, an allosteric inhibitor that 
targets selected drug-resistant EGFR mutants but spares the wild type receptor. A crystal structure 
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shows that the compound binds an allosteric site created by the displacement of the regulatory C-
helix in an inactive conformation of the kinase. The compound inhibits L858R/T790M-mutant 
EGFR with low-nanomolar potency in biochemical assays, but as a single agent is not effective in 
blocking EGFR-driven proliferation in cells due to differential potency on the two subunits of the 
dimeric receptor, which interact in an asymmetric manner in the active state8. We observe 
dramatic synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR 
dimerization9,10, rendering the kinase uniformly susceptible to the allosteric agent. EAI045 in 
combination with cetuximab is effective in mouse models of lung cancer driven by L858R/T790M 
EGFR and by L858R/T790M/C797S EGFR, a mutant that is resistant to all currently available 
EGFR TKIs. More generally, our findings illustrate the utility of purposefully targeting allosteric 
sites to obtain mutant-selective inhibitors.
Diverse activating mutations within the EGFR kinase domain give rise to a subset of non-
small cell lung cancers (NSCLCs). The L858R point mutation and small, in-frame deletions 
in the region encoded by exon 19 are the most common mutations, and are among a subset 
of oncogenic EGFR alterations that confer enhanced sensitivity to EGFR-directed TKIs11-13. 
The dose-limiting toxicity of anilinoquinazoline TKIs such as erlotinib and gefitinib arises 
from inhibition of wild type EGFR in the skin and GI tract, thus this enhanced sensitivity 
relative to wild type EGFR creates a therapeutic window that allows effective treatment of 
patients whose tumors are driven by these mutations. The T790M resistance mutation closes 
this window, in part by increasing the affinity of the mutant receptor for ATP, which in turn 
diminishes the potency of these ATP-competitive inhibitors14. Mutant-selective irreversible 
inhibitors, including the tool compound WZ400215 and and the clinical compounds 
osimertinib (AZD9291)6,16 and rociletinib (CO-1686)5, are based on a pyrimidine scaffold, 
and also incorporate a Michael acceptor group that forms a covalent bond with Cys797 at 
the edge of the ATP binding pocket. Because they bind irreversibly these agents overcome 
the enhanced ATP affinity conferred by the T790M mutation. Compounds of this class are 
demonstrating significant efficacy against T790M mutant tumors in ongoing clinical 
trials17,18, and osimertinib was recently approved by the U.S. Food and Drug Administration 
for patients with EGFR T790M-positive NSCLC following progression on prior EGFR TKI 
therapy. However, laboratory studies and early clinical experience indicate that the efficacy 
of these agents can be compromised by mutation of Cys797, which thwarts formation of the 
potency-conferring covalent bond7,15,19.
Reasoning that an allosteric inhibitor could also overcome the enhanced ATP affinity 
conferred by the T790M mutation, we screened a ~2.5 million compound library using 
purified L858R/T790M EGFR kinase. The biochemical screen was carried out using 1 μM 
ATP, and active compounds were counter-screened at 1 mM ATP and against wild type 
EGFR to identify those that were potentially non-ATP-competitive and mutant selective. 
Among the compounds identified in the screen, EGFR allosteric inhibitor-1 (EAI001, Figure 
1a) was of particular interest due to its potency and selectivity for mutant EGFR (IC50 = 
0.024 μM for L858R/T790M at 1 mM ATP, IC50 > 50 μM for wild type EGFR). Further 
characterization of the mutant-selectivity of EAI001 revealed modest potency against the 
isolated L858R and T790M mutants (0.75 μM and 1.7 μM, respectively, Extended Data Fig. 
1a). Medicinal chemistry-based optimization of this compound yielded EAI045 (Figure 1a), 
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a 3 nM inhibitor of the L858R/T790M mutant with ~1000-fold selectivity versus wild type 
EGFR at 1 mM ATP (Table 1). Enzyme kinetic characterization confirmed that the 
mechanism of inhibition was not competitive with respect to ATP (Table 1, Extended Data 
Figure 1b). Profiling of EAI045 against a panel of 250 protein kinases revealed exquisite 
selectivity; no other kinases were inhibited by more than 20% at 1 μM EAI045 (Extended 
Data Table 1). Evaluation of EAI045 in a safety pharmacology assay panel revealed 
excellent selectivity against non-kinase targets as well (Extended Data Table 2).
The crystal structure of EAI001 bound to T790M-mutant EGFR showed that the compound 
binds in an allosteric pocket that is created in part by the outward displacement of the C-
helix in the inactive conformation of the kinase (Fig. 1b,c; Extended Data Table 3). The 
compound binds as a “three-bladed propeller” with the aminothiazole moiety inserted 
between the mutant gatekeeper methionine and active site residue Lys745. The phenyl 
substituent extends into a hydrophobic cleft at the back of the pocket and is in contact with 
Leu777 and Phe856. Finally, the 1-oxoisoindolinyl group extends along the C-helix toward 
the solvent exposed exterior. The compound also forms a hydrogen bond with Asp855 in the 
DFG motif. In further support of a non-ATP competitive mechanism, the ATP-analog AMP-
PNP is bound in the expected manner in the active site cleft (Fig. 1c).
Interestingly, EGFR inhibitors neratinib20 and lapatinib21 extend into the allosteric site and 
make interactions that resemble those of two of the three blades of the allosteric agents (Fig. 
1d, Extended Data Fig. 2a, c). These ATP-competitive inhibitors are not mutant selective, 
and they span both the ATP and allosteric sites. Additionally, we note that the EGFR 
allosteric pocket is roughly analogous to a site in MEK1 that is targeted by a number of 
allosteric inhibitors that are now approved or in clinical trials22. Despite the similar location 
of the MEK allosteric site, there is no structural correspondence in the binding modes of the 
respective allosteric inhibitors (Extended Data Fig. 2a, b).
The mutant-specificity of the EGFR allosteric inhibitors arises from at least two effects. 
Most obviously, the direct contact of the aminothiazole group with the mutant gatekeeper 
methionine residue can explain the selectivity for the T790M mutant. Secondly, the 
compound cannot bind the fully inactive conformation of the wild type kinase; simple 
modeling reveals steric clashes of EAI001 with Leu858 and Leu861 in the N-terminal 
portion of the activation loop (Extended Data Fig. 3). The L858R mutation rearranges this 
portion of the activation loop23, thereby enlarging the allosteric pocket. EAI045 may also 
inhibit other mutants with a similar mechanism of activation, such as L861Q, but we do not 
expect it to inhibit most exon19 deletion variants. These mutations shorten the loop leading 
into the C-helix and may therefore prevent opening of the allosteric pocket.
Initial studies of the cellular activity of EAI045 showed that it potently decreased, but did 
not completely eliminate EGFR autophosphorylation in H1975 cells, an L858R/T790M-
mutant NSCLC cell line (Figure 2a). A similar effect was observed in NIH-3T3 cells stably 
transfected with the L858R/T790M mutant (Extended Data Fig. 4a). This inhibition was 
selective for mutant EGFR; EAI045 potently inhibited EGFR Y1173 phosphorylation in 
H1975 cells (EC50 = 2 nM), but not in HaCaT cells, a keratinocyte cell line with wild type 
EGFR (Extended Data Table 4). We observed an intermediate level of activity in the L858R-
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mutant H3255 cells, a pattern consistent with our biochemical inhibition data (Extended 
Data Table 4). Despite potent inhibition of mutant EGFR, EAI045 showed no anti-
proliferative effect in the H1975 and H3255 cell lines with concentrations as high as 10 μM 
(Extended Data Table 4). Profiling in a panel of EGFR-mutant Ba/F3 cells revealed that 
EAI045 inhibited proliferation of L858R/T790M and L858R mutant cells, but not the 
exon19del/T790M or parental Ba/F3 cells, indicative of on-target, mutant selective activity 
of the allosteric inhibitor (Extended Data Fig. 4b-e). However, half-maximal inhibition 
required ~10 μM EAI045, a concentration much higher than the biochemical IC50 of the 
compound.
In light of the incomplete inhibition of EGFR autophosphorylation and the allosteric 
mechanism of action of EAI045, we wondered to what extent ligand stimulation would 
affect inhibition of the mutant receptor. We compared inhibition of EGFR Y1173 
phosphorylation in H1975 cells in the presence and absence of exogenous EGF (10 ng/ml) 
using an ELISA-based assay. EAI045 inhibited EGFR phosphorylation with a similar EC50 
irrespective of EGF stimulation, but strikingly, inhibition plateaued at 50% in the presence 
of ligand (Fig. 2b). This phenomenon suggests two populations of receptor, one that remains 
sensitive to the allosteric inhibitor upon ligand stimulation, and another, equal in number, 
that is rendered insensitive. Ligand-induced dimerization of the EGF receptor is known to 
induce an asymmetric interaction of the kinase domains8, and is an obvious potential source 
of two receptor populations with differential inhibitor sensitivity.
In the EGFR asymmetric dimer, the C-lobe of the “activator” subunit impinges on the N-
lobe of the “receiver” subunit, inducing an active conformation in the receiver by reorienting 
the regulatory C-helix to its inward position (Fig. 2c). In wild type EGFR, only the receiver 
subunit is activated. By contrast, both subunits in a mutant receptor are expected to be 
catalytically active because oncogenic kinase domain mutations induce the active 
conformation even in the absence of ligand. As explained above, EAI045 binds a “C-helix 
out” conformation of the kinase. In the receiver subunit but not the activator, outward 
displacement of the C-helix is impeded by the asymmetric dimer interaction. Therefore we 
hypothesized that EAI045 was a potent inhibitor of the activator subunit of the mutant 
receptor, but a much less potent inhibitor of the receiver subunit, in which the C-helix is 
captive. Because the mutant receptor favors dimer formation24,25, this effect could explain 
both the incomplete inhibition of EGFR autophosphorylation and the apparent disconnect in 
the biochemical and cellular potencies of the allosteric inhibitor. To test this notion, we 
exploited an I941R point mutation in the C-lobe of the kinase, which is known to block the 
asymmetric dimer interaction8,26. The activity of the L858R/T790M mutant is dimerization-
independent26, and as expected transduction of Ba/F3 cells with L858R/T790M/I941R 
mutant EGFR led to factor-independent proliferation. In support of our hypothesis, Ba/F3 
cells bearing this dimerization-defective mutant were dramatically more sensitive to the 
allosteric inhibitor (Fig. 2d).
The therapeutic antibody cetuximab targets the extracellular portion of the EGF receptor, 
blocking ligand binding and preventing dimer formation9,10. The antibody is not effective 
clinically in EGFR-mutant NSCLC, and in cell-based studies cetuximab alone does not 
inhibit L858R/T790M or exon19del/T790M mutant EGFR, because their activity is 
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dimerization independent26. However, we reasoned that cetuximab should synergize with a 
kinase-targeted allosteric inhibitor, by converting the inhibitor-resistant receiver population 
into a monomeric form that is exquisitely sensitive to EAI045. Strikingly, in the presence of 
cetuximab (10 μg/ml), EAI045 inhibited proliferation of L858R/T790M EGFR Ba/F3 cells 
with an IC50 of approximately 10 nM, similar to its potency against this mutant in 
biochemical assays (Figure 2e). In support of an on-target, mutant-selective effect of the 
allosteric agent, proliferation of Ba/F3 cells bearing exon19del/T790M EGFR was not 
inhibited by this combination (Fig. 2f).
We next tested the in vivo efficacy of EAI045 in genetically engineered mouse model of 
L858R/T790M-mutant lung cancer27, both alone and in combination with cetuximab. Mouse 
pharmacokinetic studies with EAI045 revealed a maximal plasma concentration of 0.57 μM, 
a half-life of 2.15 h, and oral bioavailability of 26% after dosing at 20 mg/kg. In a 4-week 
efficacy study, mice were treated with EAI045 at 60 mg/kg by oral gavage once daily, either 
alone or together with cetuximab (1 mg I.P. every other day). We observed striking tumor 
regressions in the L858R/T790M-mutant mice treated with the combination, whereas those 
treated with EAI045 alone did not respond (Fig. 3a). Cetuximab alone had a very modest 
effect in these mice, as previously observed26. Mice bearing exon19del/T790M EGFR were 
treated using the same protocol, but as expected failed to respond to the combination therapy 
(Fig. 3b). MRI imaging studies of cohorts of L858R/T790M and exon19del/T790M mice 
after combination treatment for 1 or 2 weeks are shown in Extended Data Figure 5.
Mutation of C797 is expected to confer resistance to all third-generation irreversible EGFR 
inhibitors that are active on the T790M-mutant EGFR, and a preliminary study reported the 
C797S alteration in 15/67 patients (22%) with acquired resistance to AZD9291 (ref. 28). 
Mutations in C797 should not affect the efficacy of EAI045, as this residue is remote from 
the allosteric binding pocket. Consistent with this expectation, EAI045 in combination with 
cetuximab potently inhibited L858R/T790M/C797S Ba/F3 cells (Extended Data Fig. 5a) and 
treatment of genetically engineered L858R/T790M/C797S mice with the EAI045 and 
cetuximab induced marked tumor shrinkage, similar to that observed in the L858R/T790M 
models (Fig. 3c, Extended Data Fig. 5b). Pharmacodynamic studies performed following 2 
doses of treatment demonstrated that EAI045 in combination with cetuximab effectively 
inhibited phosphorylation of EGFR and downstream signaling proteins in these mice, but 
not in mice bearing the insensitive exon19del/T790M mutation (Fig 3d, e).
The compounds we describe here are amongst the first allosteric TKIs, and to our 
knowledge, the first targeting any receptor tyrosine kinase in a mutant-selective manner. 
Further study is required, but our findings suggest that EAI045 or a related compound in 
combination with an EGFR dimer-disrupting antibody such as cetuximab should be an 
effective strategy for treating L858R/T790M mutant lung cancers, as well as those with the 
triple L858R/T790M/C797S mutation, which are resistant to all current EGFR-targeted 
therapies. EAI045 and cetuximab exhibit true mechanistic synergy, a valuable property for 
combination agents because it lowers the dose required for efficacy. Ideally, 
chemotherapeutic agents used in combination should also be “orthogonal” with respect to 
mechanisms of toxicity and sensitivity to resistance mutations. EAI045 meets these criteria 
as well; its lack of activity on wild type EGFR and other kinases suggest that its dose-
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limiting toxicity is unlikely to be related to that of cetuximab and ATP-competitive EGFR 
inhibitors. In addition, given its distinct binding site, its sensitivity to resistance-conferring 
mutations is expected to be divergent from that of both cetuximab and ATP-site inhibitors. 
For these reasons, we speculate that an allosteric agent like EAI045 could be used in 
combination with ATP-site directed inhibitors, with the goal of preventing the emergence of 
treatment-associated resistance mutations in the receptor itself.
 Methods
 EGFR protein expression and purification
Constructs spanning residues 696-1022 of the human EGFR (including wild type, L858R, 
L858R/T790M, T790M, and T790M/V948R mutant sequences) were prepared in a GST-
fusion format using the pTriEX system (Novagen) for expression in Sf9 insect cells 
essentially as described14,23. EGFR kinase proteins were purified by glutathione-affinity 
chromatography followed by size-exclusion chromatography after cleavage with TEV or 
thrombin to remove the GST fusion partner following established procedures14,23.
 High-throughput screening
Purified EGFR-L858R/T790M enzyme was screened against Novartis compound collection 
of ~2.5 million using HTRF-based biochemical assay format. The screening was performed 
at 1 μM ATP using a single compound concentration (12.5 μM). 1322 top hits were picked 
for follow-up IC50 confirmation. IC50 values were determined at both 1 μM and 1 mM ATP 
to identify both ATP competitive and non-competitive compounds. Hits were also counter-
screened against wild type EGFR to evaluate the mutant selectivity.
 HTRF-based EGFR biochemical assays
Biochemical assays for wild type EGFR and each mutant were carried out using a 
homogeneous time-resolved fluorescence (HTRF) assay as described previously29. Assays 
were optimized for each ATP concentration. Compound IC50 values were determined by 12-
point inhibition curves (from 50 to 0.000282 μM) in duplicate.
 Structure determination
Prior to crystallization, 0.1 mM of EGFR-T790M/V948R was incubated for 1 hour with 0.5 
mM EAI001, 1 mM Adenosine 5′-(β,γ-imido)triphosphate (AMP-PNP) and 10 mM MgCl2 
at room temperature. Crystals of T790M/V948R EGFR in complex with EAI001 were 
prepared by hanging-drop vapor diffusion method over a reservoir solution containing 0.1M 
Bis-Tris pH5.5, 25% PEG 3350, 5mM tris (2-carboxyethyl)-phosphine (TCEP). Crystals 
were flash-frozen in liquid nitrogen after rapid immersion in a cryoprotectant solution 
containing 0.1M Bis-Tris 5.5, 25% PEG3350, 10% ethylene glycol and 5mM TCEP. 
Diffraction data were recorded using a Mar343 image plate detector on a rotating anode 
source at 100K. Data were processed and merged as described previously14. The structure 
was determined by molecular replacement with the program PHASER using an inactive 
EGFR kinase structure (PDB 2GS7) as the search model. Repeated rounds of manual 
refitting and crystallographic refinement were performed using COOT and REFMAC. The 
inhibitor was modeled into the closely fitting positive Fo-Fc electron density and then 
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included in following refinement cycles. Although the EAI001 preparation used in 
crystallization was racemic, the density clearly corresponded to the R stereoisomer and was 
modeled accordingly. Topology and parameter files for the inhibitors were generated using 
PRODRG. Statistics for diffraction data processing and structure refinement are shown in 
Extended Data Table 3.
 H1975, H3255 & HaCaT Target Modulation Assays
 Tissue Culture—Cells were maintained in 10% FBS/RPMI supplemented with 100 
μg/mL Penicillin/Streptomycin (Hyclone #SH30236.01). The cells were harvested with 
0.25% Trypsin/EDTA (Hyclone #SH30042.1), re-suspended in 5% FBS/RPMI Pen/Strep 
and plated at 7,500 cells per well in 50 μL of media in a 384-well black plate with clear 
bottoms (Greiner #789068G). The cells were allowed to incubate overnight in a 37°C, 5% 
CO2 humidified tissue culture incubator. The 12-point serial diluted test compounds were 
transferred to the plate containing cells by using a 50 nL Pin Head device (Perkin Elmer) 
and the cells were placed back in the incubator for 3 hours. All cell lines were tested and 
found negative for mycoplasma contamination using the MycoAlert Mycoplasma Detection 
Kit (Lonza).
 Phospho-EGFR (Y1173) Target Modulation Assay—HaCaT cells were stimulated 
with 10 ng/mL EGF (Peprotech # AF-100-15) for 5 minutes at room temperature. 
Constitutively activated EGFR mutant cell lines (H1975 and H3255) were not stimulated 
with EGF. The media was reduced to 20 μL using a Bio-Tek ELx 405 SelectTM plate 
washer. Cells were lysed with 20 μL of 2X Lysis buffer containing protease and phosphatase 
inhibitors (2% Triton X-100, 40 mM Tris, pH 7.5, 2 mM EDTA, 2 mM EGTA, 300 mM 
NaCl, 2X complete cocktail inhibitor (Roche #11 697 498 001), 2X Phosphatase Inhibitor 
Cocktail Set II and Set III (Sigma #P5726 and #P0044)). The plates were shaken for 20 
minutes. An aliquot of 25 μL from each well was transferred to prepared ELISA plates for 
analysis.
For the experiment studying the effect of EGF pre-treatment on EAI045 target modulation, 
H1975 cells were harvested and plated in 0.5% FBS/RPMI Pen/Strep. On the following day, 
cells were pre-treated with 0.5% FBS/RPMI media with or without 10 ng EGF/mL for 5 
minutes. Compound was added and assay was carried out as described above. The 
experiment was performed twice with duplicate samples in each experiment.
 Phospho-EGFR (Y1173) ELISA—Solid white 384-well high-binding ELISA plates 
(Greiner #781074) were coated with 5 μg/mL goat anti-EGFR capture antibody overnight in 
50 mM carbonate/bicarbonate pH 9.5 buffer. Plates were blocked with 1% BSA (Sigma 
#A7030) in PBS for 1 hour at room temperature, and washes were carried out with a Bio-
Tek ELx405 SelectTM using 4 cycles of 100 μL TBS-T (20 mM Tris, 137 mM NaCl, 0.05% 
Tween-20) per well. A 25 μL aliquot of lysed cell was added to each well of the ELISA plate 
and incubated overnight at 4°C with gentle shaking. After washing, 1:1,000 anti-phospho-
EGFR in 0.2% BSA/TBS-T was added and incubated for 2 hours at room temperature. After 
washing, 1:2,000 anti-rabbit-HRP in 0.2% BSA/TBS-T was added and incubated for 1 hour 
Jia et al. Page 7
Nature. Author manuscript; available in PMC 2016 November 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
at room temperature. Chemiluminescent detection was carried out with SuperSignal ELISA 
Pico substrate. Luminescence was read with an EnVision plate reader.
 Western blotting—Cell lysates were equalized to protein content determined by 
Coomassie Plus™ Protein Assay Reagent (ThermoScientific #1856210) and loaded onto 
4-12% NuPAGE Bis-Tris gels with MOPS running buffer with LDS Sample buffer 
supplemented with DTT. Gel proteins were transferred to PVDF membranes with an iBlot® 
Gel Transfer Device. 1X Casein-blocked membranes were probed with primary antibodies 
overnight at 4°C on an end-over-end rotisserie. Membranes were washed with TBS-T and 
HRP-conjugated secondary antibodies were added for 1 hour at room temperature. After 
washing, HRP was detected using Luminata™ Forte Western HRP Substrate reagent and 
recorded with a Bio-Rad VersaDoc imager.
 H1975, H3255 and HaCaT Proliferation Assays
H1975, H3255 and HaCaT cell lines were plated in solid white 384-well plates (Greiner) at 
500 cells per well in 10% FBS RPMI P/S media. Using a Pin Tool, 50 nL of serial diluted 
compounds were transferred to the cells. After 3 days, cell viability was measured by 
CellTiter-Glo (Promega) according to manufacturer's instructions. Luminescent readout was 
normalized to 0.1% DMSO-treated cells and empty wells. Data was analyzed by non-linear 
regression curve fitting and EC50 values were reported.
 Ba/F3 cell proliferation models
The EGFR mutant L858R, L858R/T790M, DelE746_A750/T790M, L858R/T790M/C797S 
and Del/T790M/C797S Ba/F3 cells have been previously described15. The EGFR I941R 
mutation was introduced via site directed mutagenesis using the Quick Change Site-Directed 
Mutagenesis kit (Stratagene; La Jolla, CA) according to the manufacturer's instructions. All 
constructs were confirmed by DNA sequencing. The constructs were shuttled into the 
retroviral vector JP1540 using the BD Creator™ System (BD Biosciences). Ba/F3 cells were 
infected with retrovirus and according to standard protocols, as described previously30. 
Stable clones were obtained by selection in puromycin (2 μg/ml).
Growth and inhibition of growth was assessed by MTS assay and was performed according 
to previously established methods15. Ba/F3 cells of different EGFR genotypes were exposed 
to treatment for 72 hours and the number of cells used per experiment determined 
empirically and has been previously established15. All experimental points were set up in six 
wells and all experiments were repeated at least three times. The data was graphically 
displayed using GraphPad Prism version 5.0 for Windows, (GraphPad Software; 
www.graphpad.com). The curves were fitted using a non-linear regression model with a 
sigmoidal dose response.
 NIH-3T3 cell studies
NIH-3T3 cells were infected with retroviral constructs expressing EGFR mutants according 
to standard protocols, as described previously15,19. Stable clones were obtained by selection 
in puromycin (2 μg/ml).
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 Mouse efficacy studies
EGFR-TL (L858R/T790M) and EGFR-TD (exon19del/T790M) mice were generated as 
previously described15,27. The EGFR-L858R/T790M/C797S (named as TLCS thereafter) 
mutant mouse cohort was established briefly as follows: The full-length HuTLCS cDNA 
was generated by site-directed mutagenesis using the Quickchange site directed mutagenesis 
kit (Agilent Technologies) and further verified by DNA sequencing. Sequence-verified 
targeting vectors were co-electroporated with an FLPe recombinase plasmid into v6.5 
C57BL/6J (female) x 129/sv (male) embryonic stem cells (Open Biosystems) as described 
elsewhere31. Resulting hygromycin-resistant embryonic stem clones were evaluated for 
transgene integration via PCR. Then, transgene-positive embryonic stem clones were 
injected into C57BL/6 blastocysts, and the resulting chimeras were mated with BALB/c wild 
type mice to determine germline transmission of the TLCS transgene. Further detail on the 
generation and characterization of the TLCS transgenic mice is provided in Supplementary 
Figure 3. Progeny of TL, TD and TLCS mice were genotyped by PCR of tail DNA. The TL 
and TD mice were fed a doxycycline diet at 6 weeks of age to induce EGFR TL or TD 
expression, respectively. The TLCS mice were intranasally instilled with Ad-Cre (University 
of Iowa viral vector core) at 6 weeks of age to excise the loxP sites, activating EGFR TLCS 
expression.
The EAI045 compound was dissolved in 10% NMP (10% 1-methyl-2-pyrrolidinone: 90% 
PEG-300), and was dosed at 60 mg/kg daily by oral gavage. Cetuximab was administrated at 
1 mg/mouse every other day by intraperitoneal injection. The TL, TD and TLCS mice were 
monitored by MRI to quantify lung tumor burden before being assigned to various study 
treatment cohorts, which were non-blinded and not formally randomized. All treated mice 
had an equal initial tumor burden. MRI evaluation was repeated every 2 weeks during 
treatment. The animals were imaged with a rapid acquisition with relaxation enhancement 
sequence (TR = 2000 ms, TE effect = 25 ms) in the coronal and axial planes with a 1-mm 
slice thickness gating with respiratory rates. The detailed procedure for MRI scanning has 
been previously described27. The tumor burden volumes were quantified using 3-
dimensional Slicer software. Source data for tumor volume measurements are provided in 
Supplementary Figure 2.
All care of experimental animals was in accordance with Harvard Medical School/Dana-
Farber Cancer Institute institutional animal care and use committee (IACUC) guidelines. All 
mice were housed in a pathogen-free environment at a DFCI animal facility and handled in 
strict accordance with Good Animal Practice as defined by the Office of Laboratory Animal 
Welfare. None of the tumor efficacy experiments presented in this manuscript exceeded the 
2cm maximal diameter tumor size as permitted by the Dana-Farber Cancer Institute IACUC.
 Synthesis and characterization of EAI045
 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-
thiazol-2-yl)acetamide—(EAI045) was prepared from 2-amino-2-(5-fluoro-2-
methoxyphenyl)acetic acid using a reaction sequence similar to that previously described (G. 
W. Muller, US Patent #5,698,579) followed by demethylation with boron tribromide.
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1H NMR (400 MHz, DMSO-d6) δ 12.61 (s, 1H), 9.96 (s, 1H), 7.73 (d, J=7.5 Hz, 1H), 7.66 - 
7.54 (m, 2H), 7.52 (dd, J=1.0, 7.4 Hz, 1H), 7.49 (d, J=3.6 Hz, 1H), 7.27 (d, J=3.5 Hz, 1H), 
7.11 (td, J=3.2, 8.6 Hz, 1H), 6.90 (dd, J=4.8, 8.9 Hz, 1H), 6.85 (dd, J=3.1, 9.2 Hz, 1H), 6.31 
(s, 1H), 4.61 (d, J=17.5 Hz, 1H), 3.98 (d, J=17.5 Hz, 1H); 19F NMR (376 MHz, DMSO-d6) 
δ -125.15 (s, 1F); LCMS: Rt 1.278 mins; ESMS m/z 384.20 (M + H+).
 Extended Data
Extended Data Figure 1. Inhibition of wild type and mutant EGFR kinases by EAI001 and 
EAI045 in purified enzyme assays
a, Inhibition of wild type and mutant EGFR kinases by EAI001. Activity of the indicated 
mutant EGFR kinase (residues 696-1022) was measured in the presence of increasing 
concentrations of EAI001. The HTRF assay was carried out using either 1 μM ATP (left 
panel) or 1 mM ATP (right panel). Error bars indicate standard deviation (n=2). b, Inhibition 
of L858R/T790M EGFR by EAI045 (left panel) or erlotinib (right panel) at a range of ATP 
concentrations, as indicated. Assay was performed using an HTRF-based assay as described 
in the Methods section of the main text. Error bars indicate standard deviation (n=2).
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Extended Data Figure 2. Comparison of the binding site of EGFR allosteric inhibitors with those 
of lapatinib and allosteric MEK inhibitors
a, Structure of EAI001 in complex with EGFR for comparison. b, Structure of MEK1 kinase 
bound to allosteric inhibitor GDC0973 (PDB 4AN2). GDC0973 (also called XL518) and 
other allosteric MEK inhibitors occupy a pocket created by displacement of the C-helix in 
the inactive conformation of the kinase. Most allosteric MEK inhibitors make hydrogen 
bond interactions with the γ-phosphate group of ATP that are important for their potency. 
The allosteric EGFR inhibitors we describe here bind in a generally analogous location in 
EGFR, but lack any clear structural similarity to MEK inhibitors and do not contact the γ-
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phosphate group of ATP. c, The structure of lapatinib bound to EGFR (PDB ID 1XKK). 
Both lapatinib and neratinib (see Fig. 1d in the main text) bind an inactive conformation of 
the kinase. Like gefitinib and erlotinib, both occupy the ATP site, but also extend into the 
allosteric pocket occupied by EAI001. Note that like neratinib, lapatinib places aromatic 
phenyl or pyridinyl groups in positions similar to those occupied by the aminothiazole and 
phenyl substituents of EAI001.
Extended Data Figure 3. EAI001 binding is incompatible with the inactive conformation of WT 
EGFR
Superposition of the EAI001/EGFR structure reported here with the structure of WT EGFR 
kinase in the inactive conformation (gray, PDB ID 2GS7). EAI001 (shown with carbon 
atoms in green) clashes with the side chains of leucines 858 and 861 in the WT EGFR 
structure. These leucine residues lie in a short helical segment at the N-terminus of the 
activation loop. The L858R substitution disrupts this helix. We propose that this effect 
explains, in part, the selectivity of the allosteric inhibitor for the L858R/T790M mutant. 
Note that EAI001 was crystallized with the T790M/V948R mutant EGFR, as we were 
unable to obtain crystals with the L858R/T790M or L858R/T790M/V948R proteins. The 
compound induces unstructuring of the activation loop helix and repositions L858, which is 
in contact with the 1-oxoisoindolinyl group of the inhibitor. The location and conformation 
of the inhibitor is expected to be the same in the context of the L858R mutation, but the 
details of the interaction with this portion of the activation loop will necessarily differ due to 
the mutation.
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Extended Data Figure 4. Cellular activity of EAI045
a, EAI045 inhibition of L858R/T790M EGFR in NIH-3T3 cells. Western blotting with the 
indicated concentrations of the allosteric inhibitor or with 1 μM WZ4002 as control (WZ) 
was carried out 6 h after compound addition. b-e, Profiling of EAI045 in Ba/F3 models 
bearing mutant EGFR or the parental Ba/F3 cell line, as indicted. Inhibition by WZ4002 is 
shown as a positive control. For gel source data, see Supplementary Figure 1.
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Extended Data Figure 5. Cellular and in vivo efficacy of EAI045 in combination with cetuximab
a, Ba/F3 cells bearing L858R/T790M/C797S EGFR were treated with EAI045 alone or with 
EAI045 plus cetuximab and proliferation was measured using the MTS assay after 72 hours. 
b, MRI imaging of cohorts L858R/T790M, exon19del/T790M, and L858R/T790M/C797S 
genetically engineered EGFR-mutant mice before treatment and 1 or 2 weeks after treatment 
with EAI045 and cetuximab. These cohorts of tumor bearing mice were used for short term 
efficacy and pharmacodynamic studies, and are distinct from those used for the tumor 
volume measurements shown in Fig. 3 in the main text.
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Extended Data Table 2
Selectivity of EAI045 against a panel of non-kinase targets.
Assay Name IC50 (μM)
Adenosine 2A receptor binding assay >30
Adenosine 3 receptor binding assay >30
Adrenergic Alpha 2C receptor assay >30
Alpha1A adrenergic calcium flux assay (agonist mode) >30
Alpha1A adrenergic calcium flux assay (antagonist mode) >30
Beta 1 adrenergic receptor assay >30
COX-1 assay >30
CYP3A4 Induction Reporter Gene >10
Dopamine D2 receptor assay >30
Dopamine Transporter assay >30
H1 receptor calcium assay (agonist mode) >30
H1 receptor calcium assay (antagonist mode) >30
Histamine H1 receptor assay >30
Melanocortin MC3 receptor binding assay >30
Monoamine Oxidase A assay >30
Muscarinic M1 receptor assay >30
Muscarinic M2 calcium flux assay with ATP priming (agonist mode) >30
Nicotinic (CNS) Receptor binding (human IMR32 cells) >30
Norepinephrine Transporter assay >30
PPARgamma Receptor agonist assay >30
PPARgamma Receptor antagonist assay >30
PXR Receptor agonist assay 16
PXR Receptor antagonist assay >3
Phosphodiesterase 3 assay (human platelets) >30
Phosphodiesterase 4D assay >30
Pregnane X Receptor (PXR; SXR) binding assay 7
Progesterone Receptor agonist assay >30
Progesterone Receptor antagonist assay >30
Serotonin 5HT2A calcium flux assay (agonist mode) >30
Serotonin 5HT2A calcium flux assay (antagonist mode) >30
Extended Data Table 3
Crystallographic data collection and refinement statistics.
Crystal name EGFR T790M V948R EAI001
Data collection
    Space group C2
    Cell dimensions
        a, b, c (Å) 155.1, 72.5, 76.0
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Crystal name EGFR T790M V948R EAI001
        α, β, γ (°) 90, 113.2, 90
    Resolution (Å) 42.24 - 2.31 (2.39)a
    Rmerge 0.11 (0.51)
    I/σ 10.4 (1.9)
    Completeness (%) 97.8 (94.0)
    Redundancy 3.4 (2.9)
Refinement
    Resolution (Å) 42.24 - 2.31
    No. Reflections 33377
    Rwork/ Rfree 0.174/0.206
    No. Atoms
        Protein 4826
        Ligand/ion (AMPPNP/EAI001/Mg2+) 62/25/2
        Water 398
    B-factors
        Protein 33.70
        Ligand/ion (AMPPNP/EAI001/Mg2+) 25.90
        Water 36.60
    R.m.s deviations
        Bond lengths (Å) 0.008
        Bond angles (°) 1.136
Diffraction data were recorded from a single crystal.
aValues in parentheses are for highest-resolution shell.
Extended Data Table 4
Cellular activity of EAI045 in lung cancer cell lines.
EAI045 EC50 (μM)
Cell line (EGFR) Target modulationa Proliferationb
H1975 (L858R T790M) 0.002 (4) >10 (2)
H3255 (L858R) 0.163 (4) >10 (2)
HaCaT (WT) >10 (2) >10 (1)
a
ELISA-based assay for phosphorylation of EGFR Y1173; The number of times each experiment was repeated is given in 
parentheses.
b
The number of times each experiment was repeated is given in parentheses.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Structure and binding mode of allosteric EGFR inhibitors
a, Chemical structures of EAI001 and EAI045. b, Overall view of the structure of T790M/
V948R EGFR bound to EAI001 and AMP-PNP. EAI001 is shown in CPK form with carbon 
atoms in green. The V948R substitution was introduced to allow crystallization of the kinase 
in an inactive conformation8. c, Detailed view of the interactions of EAI001. A hydrogen 
bond with Asp855 in the “DFG” segment of the kinase is shown as a dashed red line. d, The 
structure of irreversible inhibitor neratinib bound to EGFR T790M (PDB ID 2JIV). 
Neratinib occupies the ATP site, but also extends into the allosteric pocket occupied by 
EAI001.
Jia et al. Page 21
Nature. Author manuscript; available in PMC 2016 November 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Cellular activity and mechanism of synergy of EAI045 with cetuximab
a, Analysis of EAI045 inhibition of EGFR phosphorylation in H1975 cells by western 
blotting (anti-pY1068). A dose response study is shown at 3h after compound addition for 
EAI045 and the irreversible quinazoline inhibitor afatinib (control). For gel source data, see 
Supplementary Figure 1. b, The effect of EAI045 on EGFR target modulation in H1975 cells 
in the presence and absence of EGF. EGFR phosphorylation (pY1173) was measured using 
an ELISA-based assay; error bars indicate standard deviation (n=3). c, The allosteric pocket 
is differentially accessible in the two subunits of the asymmetric dimer. Unlike wild type 
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EGFR in which only the receiver subunit is active, both subunits are catalytically active in 
the L858R/T790M mutant. The activator subunit is more readily inhibited by allosteric 
agents (yellow star), because the C-helix can be readily displaced. By contrast, opening the 
allosteric pocket in the receiver subunit requires perturbing the dimer. Thus mutations that 
disrupt the asymmetric dimer (such as I941R, blue circle) or antibodies that block 
dimerization (cetuximab) should enhance the potency of allosteric agents. d, Inhibition of 
proliferation of Ba/F3 cells expressing L858R/T790M and L858R/T790M/I941R by 
EAI045. Addition of the dimer-disrupting I941R mutation markedly sensitizes to inhibition 
by EAI045. e and f, Treatment of EGFR-Mutant Ba/F3 cells with EAI045 alone, in 
combination with cetuximab (10 μg/ml), or with cetuximab alone. Note the dramatic synergy 
with cetuximab that is observed only in the L858R/T790M model.
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Figure 3. EAI045 in combination with cetuximab induces tumor regression in genetically 
engineered mouse models of EGFR-mutant lung cancer
a, Mice bearing L858R/T790M mutant tumors were treated with EAI045 alone (n=5), 
cetuximab alone (n=3) or both agents in combination (n=10). Tumor volumes were 
measured using MRI 4 weeks after initiation of treatment and are plotted for each animal in 
a “waterfall” format. b, As in panel a, but in mice bearing exon19del/T790M mutant tumors 
(n=4, 4 and 4). c, As in panel a, but in mice bearing L858R/T790M/C797S mutant tumors 
(n=3, 4, and 5). d and e, Pharmacodynamic studies in exon19del/T790M and L858R/
T790M/C797S mice. Tumor nodules from mice treated with EAI045 or cetuximab alone or 
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with the combination were analyzed by western blotting with the indicated antibodies to 
examine the effect of treatment on EGFR signaling. Multiple independent mouse tumors 
were obtained and analyzed, two independent and representative samples are shown. For gel 
source data, see Supplementary Figure 1. Source data for tumor volume measurements are 
provided in Supplementary Figure 2.
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Table 1
Inhibitory activity of EAI045 on wild type EGFR and selected mutants.
ATP (μM) EAI045 IC50 (μM)
Wild Type L858R T790M L858R T790M
1 1.6 0.076 0.049 0.002
10 1.9 0.019 0.19 0.002
100 3.5 0.009 0.5 0.003
1000 4.3 0.009 0.6 0.003
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